Sign in to view content

Brolucizumab: Will it Make a Differance

Andrew P. Schachat, MD

Video
Published 2018

Related

Biweekly Anti-VEGF Dosing for Chronic Refractory Neovascular AGe-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema
Thomas A. Ciulla, MD, MBA
Updates from the Field
2017
2 Real-World Analyses of Treatment Burden Associated With Intravitreal Injections for DME Prior to 0.2 mcg/Day Fluocinolone Acetonide (FAc)
Nancy M. Holekamp, MD
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more